

Case Report:

Sjögren-Larsson syndrome- a case report

**Dr. Prijo Philip, Dr. Sandra Premkumar, Dr. Arul Kumaran, Dr. Indu S Viswanathan,
Dr.Raghavendran V.D.**

Name of the Institute/college: Sri Manakula Vinayagar Medical College and Hospital, Puducherry

Corresponding author: Dr. Prijo Philip

Date of submission: 19 July 2014; Date of Publication: 15 September 2014

Abstract:

The present article represents a case report on a 10 year old male child with generalized dryness since infancy as well as difficulty in walking since a young age. the child presented with recurrent episodes of falling over and pruritis. the authors have concluded that a diagnosis of SLS must be considered in any neonate or infant with congenital ichthyosis and emerging neurological features.

Keywords : Sjögren-Larsson syndrome

Introduction:

Sjögren-Larsson syndrome (SLS) is inherited as an autosomal recessive disease and is associated with congenital ichthyosis, spastic diplegia or tetraplegia, and mental retardation, caused by a deficiency of fatty aldehyde dehydrogenase¹. SLS is an inborn error of lipid metabolism that is caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH), a component of fatty alcohol: NAD-oxidoreductase enzyme complex. FALDH deficiency has been found to lead to an accumulation of long-chain fatty alcohols with structural consequences for cell membrane integrity which do disrupt the barrier function of skin and the white matter of the brain². It occurs in all races and its prevalence has been estimated as 0.4 per 100,000 or lower. Over 200 cases worldwide have been reported³. The case report is as follows.

Case report:

A 10 year old male child born of second degree consanguinity, presented to the pediatric out -patient

department with generalized dryness of skin since infancy and difficulty in walking since the age of 3-4 years. He had recurrent episodes of falling over and there was waxing and waning of pruritis, the episodes lasting 20 days every 2-3 months. Stiffness in lower limbs started in later part of the first year of life with progressive increase up to the time of presentation. The child was delivered at full term by normal vaginal delivery and he had an uneventful post natal period. Further, it was found that the child had attained head holding at 6 months, sitting without support at 1 year age and walking with support at 2 years. Neurological examination revealed mental retardation, increased tone in both lower limbs, brisk deep tendon reflexes, and bilateral extensor plantar response suggestive of spastic diplegia. The upper limbs did not show any tone or deep tendon reflex abnormalities. There was also evidence of conduction aphasia in the child. Sensory system was normal. Skeletal, dental, eye/ fundus examination and eye or limb movements were normal. Child also had

microcephaly. Scholastic performance was poor. Skin examination showed scaly ichthyotic lesions with severe pruritus affecting all body parts and which started in late infancy on the face, neck and abdomen. Chest radiograph and all routine hematological investigations were normal. Skin biopsy revealed hyperkeratosis dermis with non-specific peridermal inflammation. MRI revealed cerebral atrophy. BERA revealed sensory neural hearing loss. The patient showed progressive worsening of ataxia and diplopia and eventually became bed ridden. However, the ichthyosis was seen to improve. The patient is currently on regular follow up. The discussion is as follows.

Discussion:

In 1957, Sjögren and Larsson described a rare syndrome that was characterized by congenital ichthyosis associated with spastic diplegia or tetraplegia (spastic pyramidal symptoms), aphasia, and low-grade dementia⁴. SLS is an inherited neurocutaneous disorder and it is caused by mutations in the ALDH3A2 gene that is found to encode fatty aldehyde dehydrogenase (FALDH). Over 70 mutations in ALDH3A2 have been discovered in SLS patients including amino acid substitutions, deletions, insertions, and splicing errors⁵. Unfortunately, the diagnosis of SLS is almost always delayed because usually only cutaneous symptoms are present at birth.

Newborns may manifest symptoms and signs of the disease (first ichthyosis, subsequently neurologic symptoms). Spasticity may be apparent before age 3 years and is more severe in the lower limbs than in other parts of the body⁶. The diagnosis must be considered in all patients with generalized hyperkeratosis and central nervous system dysfunction. Glistening dots in the macular region is

considered pathognomonic, although it is not constant. The nature of the crystalline deposits in the retina is unclear. It is postulated that they might represent accumulations of long-chain fatty alcohols or fatty aldehydes⁷. There is also spastic diplegia, occasionally tetraplegia, with mental retardation, epilepsy, speech defects, dental, dermatological, skeletal, and retinal changes⁸. Skin manifestations are in the form of ichthyosis which is a generalized hyperkeratosis of the trunk, joints, and the dorsal aspects of the hands and the feet. Neuropathologically, the hallmark of SLS is demyelination of the cerebral white matter and corticospinal and vestibulospinal tracts that is responsible for spasticity⁹. Recently, few reports have described the use of proton MRI spectroscopy in Sjogren-Larsson syndrome which shows abnormal lipid peak at 1.3 ppm at both TE-30 and 135 ms in the area of T2 white matter abnormalities². Management in SLS is supportive¹⁰ and mainly involves topical moisturizing lotion, keratolytic agents and oral retinoids. Training to provide home-based physical therapy is useful to prevent contractures.

Conclusion:

In conclusion, the diagnosis of SLS must be considered in any neonate or infant with congenital ichthyosis and emerging neurological features. Ocular features and pruritus must be looked for. Cerebral MRI reveals arrested myelination or demyelination in white matter and lipid peak on spectroscopy helps in making the diagnosis. However, spectroscopy is a rare resource and is not readily available to be made use of in a country such as ours, which is why a high degree of suspicion based on the clinical findings alone will go a long way in reducing the morbidity and mortality due to this condition.

References:

1. Ganemo A, Jagell S, Vahlquist A. Sjogren-Larsson syndrome: A study of clinical symptoms and dermatological treatment in 34 Swedish patients. *Acta Derm Venerol.* 2009;89:68–73.
2. Nakayama M, Távora DG, Alvim TC, Araújo AC, Gama RL. MRI and 1H-MRS findings of three patients with Sjogren-Larsson syndrome. *Arq Neuropsiquiatr.* 2006;64:398–401.
3. Richards BW, Rundle A, Wilding A: Congenital ichthyosis, spastic diplegia and mental deficiency. *I Ment Def Res* 1957, 1:118-129.
4. Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders. *Acta Psychiatr Scand.* 1957;32:1–108.
5. Rizzo WB. Sjogren-Larsson syndrome: Molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. *Mol Genet Metab.* 2007;90:1–9.
6. Carney G, Wei S, Rizzo WB: Sjögren-Larsson syndrome: seven novel mutations in the fatty aldehyde dehydrogenase gene ALDH3A2. *Hum Mutat* 2004, 24:186.
7. Willemsen MA, Cruysberg JR, Rotteveel JJ, Aandekerk AL, van Domburg PH, Deutman AF: Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. *Am J Ophthalmol* 2000, 130:782-789.
8. Dutra LA, de Aquino CC, Barsottini OG. Sjogren-Larsson syndrome: Case report and review of neurologic abnormalities and ichthyosis. *Neurologist.* 2009;15:332–4.
9. Wester P, Bergstrom U, Brun A, Jagell S, Karlsson B, Eriksson A. Monoaminergic dysfunction in Sjogren-Larsson syndrome. *Mol Chem Neuropathol.* 1991;15:13–28.
10. Sood M, Trehan A, Dinakaran J, Marwaha RK: Sjögren-Larsson syndrome. *Indian J Pediatr* 2002, 69:193-194.